Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levofloxacin-containing dual therapy vs bismuth-based quadruple therapy for Helicobacter pylori eradication
ChiCTR2400088791Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of levofloxacin in Helicobacter pylori infection (2 arms), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: Helicobacter pylori eradication by 13C-urea breath test. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
levofloxacin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2400088791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088791.